BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL kinase inhibitors, including imatinib. It has also been shown in vitro that mutations outside the kinase domain in the neighboring linker, SH2,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sherbenou, Daniel W., Hantschel, Oliver, Kaupe, Ines, Willis, Stephanie, Bumm, Thomas, Turaga, Lalita P., Lange, Thoralf, Dao, Kim-Hien, Press, Richard D., Druker, Brian J., Superti-Furga, Giulio, Deininger, Michael W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2010
Gaiak:
Myeloid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2995357/
https://ncbi.nlm.nih.gov/pubmed/20519627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-10-183665
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak